There is no evidence to support or refute the use of oral NSAIDs to treat neuropathic pain conditions.
P L A I N L A N G U A G E S U M M A R Y

Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for neuropathic pain in adults
Neuropathic pain is pain which comes from damaged nerves, spinal cord, or brain. It is different from pain messages that are carried along healthy nerves from damaged tissue (for example, a fall or cut, or arthritic knee). Neuropathic pain is treated by different medicines to those used for pain from damaged tissue. Medicines that are sometimes used to treat depression or epilepsy can be very effective in some people with neuropathic pain.
Commonly used painkillers such as ibuprofen (a nonsteroidal anti-inflammatory drug, or NSAID) are not usually considered to be effective in treating neuropathic pain, but in some parts of the world they are used commonly for neuropathic pain conditions.
In May 2015 we searched for clinical trials in which oral NSAIDs were used to treat neuropathic pain in adults. We found only two small studies that included 251 participants who had chronic low back pain with a neuropathic component, or had neuropathic pain after shingles. Of these 251 participants, 209 were in a study of an experimental drug that is not licensed and not available for use.
The trial results show that there was no difference between NSAIDs and placebo in terms of pain or adverse events (very low quality evidence). There is no good evidence to tell us whether or not oral NSAIDs are helpful to treat neuropathic pain conditions.
B A C K G R O U N D
The protocol for this review was based on a template for reviews of drugs used to relieve neuropathic pain. The aim was for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (Moore 2010a; Moore 2012a; Appendix 1).
Description of the condition
The 2011 International Association of the Study of Pain definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (Jensen 2011), based on an earlier consensus meeting (Treede 2008) . Neuropathic pain is a consequence of a pathological maladaptive response of the nervous system to 'damage' from a wide variety of potential causes. It is characterised by pain in the absence of a noxious stimulus and may be spontaneous (continuous or paroxysmal) in its temporal characteristics or be evoked by sensory stimuli (dynamic mechanical allodynia where pain is evoked by light touch of the skin). Neuropathic pain is associated with a variety of sensory loss (numbness) and sensory gain (allodynia) clinical phenomena, the exact pattern of which vary between patient and disease, perhaps reflecting different pain mechanisms operating in an individual patient and therefore potentially predictive of response to treatment (Demant 2014; Neuropathic pain is usually divided according to the cause of nerve injury. There may be many causes, but some common causes of neuropathic pain include diabetes (painful diabetic neuropathy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation (phantom limb pain), neuropathic pain after surgery or trauma, stroke or spinal cord injury, trigeminal neuralgia, and human immunodeficiency virus (HIV) infection. Many people with neuropathic pain conditions are significantly disabled with moderate or severe pain for many years. Chronic pain conditions comprised five of the 11 top-ranking conditions for years lived with disability in 2010 (Vos 2012), and are responsible for considerable loss of quality of life, employment, and increased healthcare costs (Moore 2014a). In systematic reviews, the overall prevalence of neuropathic pain in the general population is reported to be between 7% and 10% (van Hecke 2014), and about 7% in a systematic review of studies published since 2000 (Moore 2014a). In individual countries, prevalence rates have been reported as 3.3% in Austria (Gustorff 2008), 6.9% in France (Bouhassira 2008), and up to 8% in the UK (Torrance 2006). Some forms of neuropathic pain, such as PDN and post-surgical chronic pain (which is often neuropathic in origin), are increasing (Hall 2008). The prevalence of PHN is likely to fall if vaccination against the herpes virus becomes widespread. Estimates of incidence vary between individual studies for particular origins of neuropathic pain, often because of small numbers of cases. In primary care in the UK between 2002 and 2005, the incidences (per 100,000 person-years' observation) were 28 (95% confidence interval (CI) 27 to 30) for PHN, 27 (26 to 29) for trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain, and 21 (20 to 22) for PDN (Hall 2008). However, the incidence of trigeminal neuralgia has also been estimated at 4 in 100,000 per year (Katusic 1991; Rappaport 1994), and 12.6 per 100,000 person-years for trigeminal neuralgia and 3.9 per 100,000 person-years for PHN in a study of facial pain in the Netherlands (Koopman 2009). One systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as PDN, can be more common than other neuropathic pain conditions, with prevalence rates up to 400 per 100,000 person-years (McQuay  2007) . Neuropathic pain is known to be difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. A multidisciplinary approach is now advocated, with pharmacological interventions being combined with physical or cognitive interventions, or both. Conventional analgesics are usually not effective, but without evidence to support or refute that view. Some people with neuropathic pain may derive some benefit from a topical lidocaine patch or low concentration topical capsaicin, though evidence about benefits is uncertain ( The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction; Moore 2013b) is small, generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNT) usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuropathic pain is not particularly different from other chronic pain conditions in that only a small proportion of trial participants have a good response to treatment (Moore 2013a). The current National Institute for Health and Care Excellence (NICE) guidance suggests offering a choice of amitriptyline, duloxetine, gabapentin, or pregabalin as initial treatment for neuropathic pain (with the exception of trigeminal neuralgia), with switching if first, second, or third drugs tried are not effective or not tolerated (NICE 2013) . This concurs with other recent guidance (Finnerup 2015).
Description of the intervention
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used analgesics in general (Laine 2001). NSAIDs act by inhibiting the cyclooxygenases (COXs), which synthesise prostaglandins that are involved in inflammation and pain. The analgesic and anti-inflammatory actions of NSAIDs are attributed to the inhibition of cyclooxygenase-2 (COX-2), while their adverse gastrointestinal effects are attributed to the inhibition of cyclooxygenase-1 (COX-1). Traditional NSAIDs such as ibuprofen are non-selective. COX-2-selective NSAIDs were thus developed to reduce adverse gastrointestinal effects, but were later found to increase the risk of myocardial infarction and stroke. Therefore, rofecoxib and valdecoxib have been withdrawn from the market (EMEA 2005; FDA 2004 ). However, some traditional NSAIDs with relative selectivity for COX-2 were also found to increase the risk of myocardial infarction (Grosser 2011).
How the intervention might work
One current hypothesis is that damage to the peripheral nerves is followed by an inflammatory reaction that relates to increased production of prostaglandins, amplifying sodium currents and calcium influx in peripheral nociceptive neurons, and enhancing neu- 
Why it is important to do this review
Although often considered to lack adequate evidence, NSAIDs are widely used in the management of neuropathic pain (Di Franco 2010; Vo 2009). Previous surveys found 18% to 47% of affected people reported using NSAIDs specifically for their neuropathic pain (Vo 2009), although possibly not in the UK (Hall 2013). It is therefore desirable to assess the best evidence on the efficacy and safety of NSAIDs in managing neuropathic pain. In chronic pain generally, and neuropathic pain in particular, few drugs produce the good level of pain relief that patients want in more than a minority of patients (Moore 2013a), which makes proper review of efficacy and harm important. This review will assist policy makers, physicians, and consumers to make decisions regarding the use of NSAIDs in managing neuropathic pain. The standards used to assess evidence in chronic pain trials have changed substantially, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using average pain scores, or average change in pain scores, to the number of patients who have a large decrease in pain (by at least 50%); this level of pain relief has been shown to correlate with improvements in comorbid symptoms, function, and quality of life. Trials included and analysed needed to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc) and size (ideally at least 500 participants in a comparison in which the NNT is 4 or above) (Moore 1998; Moore 2010a). This sets high standards and marks a departure from how systematic reviews have been conducted previously. These standards have been set out in the authors' reference guide for the Cochrane Pain, Palliative, and Supportive Care Review Group (Cochrane PaPaS Group 2012). This Cochrane systematic review used the standards to assess evidence and take both statistical and clinical significance into consideration, in order to provide an overview of the analgesic efficacy and safety of NSAIDs for neuropathic pain.
O B J E C T I V E S
To assess the analgesic efficacy of oral nonsteroidal anti-inflammatory drugs (NSAIDs) for chronic neuropathic pain in adults, when compared to placebo or another active intervention, and the adverse events associated with its use in clinical trials.
M E T H O D S Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with doubleblind assessment of participant outcomes following two weeks of treatment or longer, although the emphasis of the review was on studies of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts (usually reports of meetings). We excluded studies that were non-randomised, studies of experimental pain, case reports and clinical observations.
Types of participants
Studies included adult participants aged 18 years and above. Participants had one or more of a wide range of chronic neuropathic pain conditions including:
1 Where studies included participants with more than one type of neuropathic pain, we planned to analyse results according to the primary condition.
Types of interventions
We included studies using NSAIDs at any dose, by oral route, administered for the relief of neuropathic pain and compared to placebo or any active comparator (for example, another NSAID).
Types of outcome measures
We anticipated that studies would use a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity or pain relief, or both. We were particularly interested in the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These outcomes are different from those used in most earlier reviews (Seidel 2013), concentrating as they do on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (O'Brien 2010). Our preferred time point of outcome measures was at week 12, which is considered a standard measurement point and is typically required by regulatory bodies (Moore 2010a). However, we anticipated that there would be very limited data, and have included studies that reported outcomes at other time points, from two weeks onwards. We planned to include a 'Summary of findings' 1. Any pain-related outcome indicating some improvement 2. Withdrawals due to lack of efficacy 3. Participants experiencing any adverse event 4. Participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is lifethreatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the patient, or may require an intervention to prevent one of the above characteristics/consequences.
5. Withdrawals due to adverse events 6. Specific adverse events, particularly somnolence and dizziness
Search methods for identification of studies Electronic searches
We searched the following databases, without language restrictions.
• Cochrane Central Register of Controlled Trials (CENTRAL, via the Cochrane Register of Studies Online database (CRSO)) to 29 May 2015.
• MEDLINE (via Ovid) from 1946 to 29 May 2015.
• EMBASE (via Ovid) from 1974 to 29 May 2015.
The search strategies for CENTRAL, MEDLINE, and EMBASE are listed in Appendix 2, Appendix 3, and Appendix 4, respectively.
Searching other resources
We reviewed the bibliographies of identified RCTs and review articles, contacted authors and known experts in the field, and searched ClinicalTrials.gov (ClinicalTrials.gov) and World Health Organization International Clinical Trials Registry Platform (IC-TRP) (apps.who.int/trialsearch/) to identify additional published or unpublished data.
Data collection and analysis
We have included a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart (Liberati 2009).
Selection of studies
We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy inclusion criteria, and we obtained full copies of the remaining studies. Two review authors read these studies independently and reached agreement by discussion. We did not anonymise the studies in any way before assessment.
Data extraction and management
Two review authors independently extracted data using a standard form and checked for agreement before entry into the Cochrane Collaboration's statistical software, Review Manager 2014, or any other analytical tool. We included information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow-up, analgesic outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, or a serious adverse event).
Assessment of risk of bias in included studies
We used the Oxford Quality Score as the basis for inclusion, limiting inclusion to studies that were randomised and double-blind as a minimum (Jadad 1996). Two authors independently assessed the risk of bias in each study, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion.
We assessed the following for each study. 1. Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, eg random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non-random process (eg odd or even date of birth; hospital or clinic record number).
2. Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (eg telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation and were, therefore, at a high risk of bias (open list) (eg open list).
3. Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, eg identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies that were not double-blind.
4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study and/or used 'baseline observation carried forward' analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis).
5. Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 or more participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate the NNT as the reciprocal of the absolute risk reduction (ARR) (McQuay 1998). For unwanted effects, the NNT would became the number needed to treat to harm (NNH) and be calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CIs) using a fixed-effect model unless we found significant statistical heterogeneity (Assessment of heterogeneity). We would not use continuous data in analyses. In the event, we did not carry out any analysis.
Unit of analysis issues
We accepted randomisation to individual participant only. The control treatment arm would be split between active treatment arms in a single study if the active treatment arms were not combined for analysis.
Dealing with missing data
We planned to use an intention-to-treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post-baseline assessment. Missing participants would be assigned zero improvement where possible. In the event, we did not carry out any analysis.
Assessment of heterogeneity
We planned to deal with clinical heterogeneity by combining studies that examined similar conditions. We planned to assess statistical heterogeneity visually (L'Abbé 1987), and using the I 2 statistic. When the I 2 value was greater than 50%, we intended to consider possible reasons for this. There were insufficient data to carry out any assessment of heterogeneity.
Assessment of reporting biases
The aim of this review was to use dichotomous data of known utility (Moore 2010d). The review did not depend on what authors of the original studies chose to report or not, although clearly difficulties arose if studies failed to report dichotomous results. We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher) (Moore 2008). In the event there were insufficient data to assess publication bias.
Data synthesis
We planned to analyse according to individual painful conditions, because placebo response rates with the same outcome can vary between conditions, as can the drug-specific effects (Moore 2009a). We would use a fixed-effect model for meta-analysis, but planned to use a random-effects model if there was significant clinical heterogeneity and it was considered appropriate to combine studies. We examined data for each painful condition in three tiers, according to outcome and freedom from known sources of bias. The first tier used data meeting current best standards, where studies reported the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of last observation carried forward (LOCF) or other imputation method other than baseline observation carried forward (BOCF) for dropouts, reported an ITT analysis, lasted eight or more weeks, had a parallel-group design, and had at least 200 participants (preferably at least 400) in the comparison (Moore 2010a; Moore 2012a). We planned to report these top-tier results first. The second tier used data from at least 200 participants, but where one or more of the above conditions was not met (for example, reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks). The third tier of evidence used data from fewer than 200 participants, or where there were expected to be significant problems because, for example, of very short duration studies of less than four weeks, where there was major heterogeneity between studies, or where there were shortcomings in allocation concealment, attrition, or incomplete outcome data. For this third tier of evidence, no data synthesis is reasonable, and may be misleading, but an indication of beneficial effects might be possible.
In the event, no pooling of data was possible because there were not at least two studies involving at least 200 participants that reported dichotomous data in any one type of neuropathic pain.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses to investigate heterogeneity according to:
1. different dosages of NSAIDs; 2. different time points of outcome measurement. However, there were insufficient data.
Sensitivity analysis
We planned to conduct a sensitivity analysis by excluding studies with high risk of bias (having one or more domains on the 'Risk of bias' tool judged as 'high risk' as per the guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), with all remaining trials judged at low risk of bias). However, there were insufficient data.
R E S U L T S Description of studies
Results of the search
Electronic searches identified 181 records in CENTRAL, 464 in MEDLINE, and 385 in EMBASE. After de-duplication and screening we retained 10 possible studies for inclusion. Searches of on-line clinical trial registries identified a further four. Figure 1 shows the flow diagram of study selection. Nine studies did not fulfil the entry criteria and three from ClinicalTrials.gov were either terminated or are still ongoing, but without any results. That left two studies for inclusion (251 participants). 
Risk of bias in included studies
The Oxford Quality scores for the included studies were 3 or 4 out of 5. Neither study described blinding in detail. Figure 2 shows the 'Risk of bias' summary. 
Allocation
One study had low risk of bias for sequence generation (Romano 2009), but there were no details for allocation concealment. The other study did not report methods for either sequence generation or allocation concealment, and was judged to be at unclear risk of bias for this domain (Shackelford 2009.
Blinding
Both studies reported being double blind, but no methods were described.
Incomplete outcome data
One study reported only on completers, and we judged it to be at high risk of bias (Romano 2009). The other used LOCF imputation, and we judged the risk of bias as unclear in the circumstance of a short duration study (Shackelford 2009).
Selective reporting
We found no selective reporting bias.
Other potential sources of bias
Small size was a problem (high risk of bias) for Romano 2009, as it reported on only 16 participants who had a neuropathic component to their pain according to the study's strict diagnostic criteria. The other study had around 70 participants per group, and we judged that study to be at unclear risk of bias for this domain (Shackelford 2009).
Effects of interventions Efficacy of NSAIDs
Given the small number of studies and the small size of the studies, there was no top tier evidence, and no second tier evidence. Only third tier evidence was available. We present efficacy results for the studies in Appendix 5. Romano 2009 reported only on pre-treatment and 4-week posttreatment with a celecoxib dose of 3 to 6 mg/kg/day (200 to 400 mg daily) in 16 participants with chronic low back pain and a Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score of 12 and above. The mean pre-treatment pain score was 47/ 100 mm, and the mean post-treatment score was 46/100 mm. By contrast, the post-treatment score was significantly reduced with both pregabalin and pregabalin plus celecoxib. Shackelford 2009 reported on 25 mg and 50 mg of an experimental NSAID, GW406381, compared with placebo over three weeks of treatment in 209 participants with postherpetic neuralgia. For no outcome was there a statistically significant difference between GW406381 and placebo.
Adverse events and withdrawals
There were too few data to draw any conclusions about adverse events and withdrawals, details of which are in Appendix 6. There were numerically slightly more adverse events and withdrawals with GW406381 than with placebo in Shackelford 2009. Serious adverse events were reported in 4/143 participants with GW406381 and none with placebo (Shackelford 2009). No deaths were reported in either study.
D I S C U S S I O N
Summary of main results
The main result was that there was no useful information to make judgements about the efficacy or safety of oral NSAIDs in treating neuropathic pain in general, or for any specific neuropathic pain condition. Only 225 participants in two included studies provided any information, and only 16 for an NSAID (celecoxib) likely to be used in clinical practice. Romano 2009 defined neuropathic pain on the basis of Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score. There are difficulties with the case definition of neuropathic pain used in this study, and we are uncertain that the use of the LANSS scale alone is adequately able to distinguish a neuropathic component from the pain originating from other sources. We are uncertain concerning the hypothetical scenario of a patient with LANSS score greater than 12 but who could quite conceivably have a combination of non-neuropathic and neuropathic pain (ie, a high LANSS score might identify a case of neuropathic pain, but it does not exclude co-existent non-neuropathic pain), especially if these are occurring in the same site. Interpretation of the results is difficult, not just because of the small numbers. It is worth noting that GW406381, which showed no efficacy in postherpetic neuralgia ( Despite the drug not being available, therefore, the study provides the best evidence we have that NSAIDs may not be effective in neuropathic pain. Most of the excluded studies or the ongoing studies would not have provided any additional useful evidence. Patarica-Huber 2011, in a randomised but open study, found no additional benefit from adding diclofenac to gabapentin in 75 participants with neuropathic pain after anti-neoplastic therapy for breast cancer.
Overall completeness and applicability of evidence
The evidence available was almost completely irrelevant to clinical practice. NSAIDs were used commonly for treating neuropathic pain in a recent review (Vo 2009), though not apparently in the UK (Hall 2013); the lack of any evidence to support this use is surprising. The striking discrepancy between the widespread use of NSAIDs by patients with neuropathic pain and an apparent consensus among pain specialists that these medications lack efficacy for neuropathic pain is not helped by this review. The absence of any reliable evidence of NSAID efficacy is a challenge to their continued widespread use.
Quality of the evidence
The quality of the evidence was poor. We identified two studies, only one of which used an intervention that is available, and only 16 participants in that study met our inclusion criteria. The study did not report any of our primary outcomes, which are of known clinical validity, but reported group mean results for an outcome that does not as a rule have a Gaussian distribution.
Potential biases in the review process
We know of no potential biases in the review process. We carried out a comprehensive search of the databases most likely to include relevant studies, and together with our own and our colleagues' knowledge of this treatment area, we consider it unlikely that there is a large body of unidentified or unpublished evidence showing a large effect from oral NSAIDs.
Agreements and disagreements with other studies or reviews
The results of this review, which show very little evidence concerning NSAIDs in neuropathic pain, reflect those of a similar previous review (Vo 2009). Neither the current NICE guidance, nor a large systematic review of pharmacotherapy for this population, mention using NSAIDs for neuropathic pain (Finnerup 2015; NICE 2013).
A U T H O R S ' C O N C L U S I O N S Implications for practice
For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion that oral NSAIDs have any efficacy in any neuropathic pain condition.
For clinicians
There is insufficient evidence to support or refute the suggestion that oral NSAIDs have any efficacy in any neuropathic pain condition. The absence of any reliable evidence of oral NSAID efficacy is a challenge to their continued widespread use.
For policy makers
There is insufficient evidence to support or refute the suggestion that oral NSAIDs have any efficacy in any neuropathic pain condition, and in the absence of any supporting evidence they should probably not be recommended.
For funders
Implications for research
General
Large, robust randomised trials with patient-centred outcomes would be required to produce evidence to support or refute efficacy of NSAIDs in neuropathic pain.
Design
There are no implications for design of studies.
Measurement (endpoints)
There are no implications for measurement.
Comparison between active treatments
NSAIDs cannot be compared with other treatments for neuropathic pain with established efficacy.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Romano 2009
Methods Randomised, double-blind, cross-over (4 weeks each treatment, with 1 week washout) 
D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S Appendix 1. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful conditions. The outcomes are now better defined, particularly with new criteria of what constitutes moderate or substantial benefit (Dworkin 2008); older trials may only report participants with 'any improvement'. Newer trials tend to be larger, avoiding problems from the random play of chance. Newer trials also tend to be longer, up to 12 weeks, and longer trials provide a more rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain, and we are now applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that may affect our overall assessment.
The following are some of the recent insights that must be considered in this new review. 1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore 2011a; Moore 2011b), back pain (Moore 2010b), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases average results usually describe the experience of almost no-one in the trial. Data expressed as averages are potentially misleading, unless they can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually from pain changes or patient global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In arthritis, trials shorter than 12 weeks, and especially those shorter than eight weeks, overestimate the effect of treatment (Moore 2009b); the effect is particularly strong for less effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of patients with at least moderate benefit can be small, even with an effective medicine, falling from 60% with an effective medicine in arthritis, to 30% in fibromyalgia 4. Finally, presently unpublished individual patient analyses indicate that patients who get good pain relief (moderate or better) have major benefits in many other outcomes, affecting quality of life in a significant way (Moore 2010d).
